About: Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors
Creator	Lin, Chih-Sheng Wu, Vin-Cent Chen, Cheng-Yi Chen, Han-Hsiang Huang, Tao-Min Lin, Yu-Feng Pan, Chi-Feng Wu, Chih-Jen Chen, ; Lin, ; Cheng-Jui Wu, Jen
Source	Elsevier; Medline; PMC
abstract	Abstract Objective To focus on the potential beneficial effects of the pleiotropic effects of dipeptidyl peptidase-4 inhibitors (DPP4is) on attenuating progression of diabetic kidney disease in reducing the long-term effect of the acute kidney injury (AKI) to chronic kidney disease (CKD) transition. Patients and Methods Data from the National Health Insurance Research Database from January 1, 1999, to July 31, 2011, were analyzed, and patients with diabetes weaning from dialysis-requiring AKI were identified. Cox proportional hazards models and inverse-weighted estimates of the probability of treatment were used to adjust for treatment selection bias. The outcomes were incident end-stage renal disease (ESRD) and mortality, major adverse cardiovascular events, and hospitalized heart failure. Results Of a total of 6165 patients with diabetes weaning from dialysis-requiring AKI identified, 5635 (91.4%) patients were DPP4i nonusers and 530 (8.6%) patients were DPP4i users. Compared with DPP4i nonusers, DPP4i users had a lower risk of ESRD (hazard ratio, 0.81; 95% CI, 0.70-0.94; P=.04) and all-cause mortality (hazard ratio, 0.28; 95% CI, 0.23-0.34; P<.001) after adjustments for CKD, advanced CKD, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use. In contrast, the risk of major adverse cardiovascular events and hospitalized heart failure did not differ significantly between groups. Conclusion Dipeptidyl peptidase-4 inhibitor users had a lower risk of ESRD and mortality than did nonusers among patients with diabetes after weaning from dialysis-requiring AKI. Therefore, a prospective study of AKI to CKD transitions after episodes of AKI is needed to optimally target DPP4i interventions.
has issue date	2018-12-31(xsd:dateTime)
bibo:doi	10.1016/j.mayocp.2018.06.023
bibo:pmid	30343892
has license	els-covid
sha1sum (hex)	7a4af315986354d77cdebc2cad88d482d8d2d59d
schema:url	https://doi.org/10.1016/j.mayocp.2018.06.023
resource representing a document's title	Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors
has PubMed Central identifier	PMC7126857
has PubMed identifier	30343892
schema:publication	Mayo Clinic Proceedings
resource representing a document's body	covid:7a4af315986354d77cdebc2cad88d482d8d2d59d#body_text
is schema:about of	named entity 'EPISODES' named entity '0.94' named entity '0.28' named entity 'INCIDENT' named entity 'USE' named entity 'LONG-TERM EFFECT' named entity '6165' named entity 'WEANING FROM DIALYSIS' named entity 'FOCUS' named entity 'PROGRESSION' named entity 'DIABETIC KIDNEY DISEASE' named entity 'COMPARED' named entity 'NEEDED' named entity 'IDENTIFIED' named entity 'TREATMENT SELECTION' named entity 'ANGIOTENSIN II RECEPTOR BLOCKER' named entity 'TOTAL' named entity 'POTENTIAL' named entity 'MORTALITY' named entity 'INTERVENTIONS' named entity '288' named entity 'CONCLUSION' named entity 'END-STAGE RENAL DISEASE' named entity 'TARGET' named entity 'OBJECTIVE' named entity 'AKI' named entity 'TO ADJUST' named entity 'REDUCING' covid:arg/7a4af315986354d77cdebc2cad88d482d8d2d59d named entity 'PATIENTS' named entity 'METHODS' named entity 'RESEARCH' named entity '5635' named entity 'ACUTE KIDNEY INJURY' named entity 'INVERSE' named entity 'ADJUSTMENTS' named entity 'SELECTION BIAS' named entity 'USERS' named entity 'CARDIOVASCULAR EVENTS' named entity 'MAJOR' named entity 'RISK OF' named entity 'BENEFICIAL' named entity 'NATIONAL HEALTH INSURANCE' named entity 'DATA' named entity 'ANALYZED' named entity 'PROSPECTIVE STUDY' named entity 'GROUPS' named entity 'ADVANCED' named entity 'TRANSITION' named entity 'WEIGHTED' named entity 'ESRD' named entity 'EFFECTS' named entity 'CHRONIC KIDNEY DISEASE' named entity 'DID' named entity 'CKD' named entity 'RESULTS' named entity 'HOSPITALIZED' named entity 'DIABETES' named entity 'LOWER' named entity 'ESTIMATES' named entity 'DATABASE' named entity 'DIPEPTIDYL PEPTIDASE-4 INHIBITOR' named entity 'ANGIOTENSIN-CONVERTING ENZYME INHIBITOR' named entity 'CONTRAST' named entity 'TREATMENT' named entity 'USED' named entity 'DIPEPTIDYL PEPTIDASE-4 INHIBITORS' named entity 'RATIO' named entity 'COX PROPORTIONAL HAZARDS MODELS' named entity 'HEART FAILURE' named entity 'PATIENTS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software